Compared with placebo , teriflunomide significantly reduced the risk of relapse defining clinically definite multiple sclerosis at the 14 mg dose ( hazard ratio [ HR ] 0574 [ 95 % CI 0379-0869 ] ; p = 00087 ) and at the 7 mg dose ( 0628 [ 0416-0949 ] ; p = 00271 ) .